Avvisati G - Search Results

1

Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment.

Petrucci MT, Avvisati G, Tribalto M, Cantonetti M, Giovangrossi P, Mandelli F. Petrucci MT, et al. Among authors: avvisati g. Eur J Haematol. 1989 Mar;42(3):233-7. doi: 10.1111/j.1600-0609.1989.tb00104.x. Eur J Haematol. 1989. PMID: 2924885

2

The role of interferon-alpha in the management of myelomatosis.

Avvisati G, Mandelli F. Avvisati G, et al. Hematol Oncol Clin North Am. 1992 Apr;6(2):395-405. Hematol Oncol Clin North Am. 1992. PMID: 1582981 Review.

3

Biology and treatment of multiple myeloma.

Mandelli F, Avvisati G, Tribalto M. Mandelli F, et al. Among authors: avvisati g. Curr Opin Oncol. 1992 Feb;4(1):73-86. doi: 10.1097/00001622-199202000-00010. Curr Opin Oncol. 1992. PMID: 1591296 Review.

4

[Interferon: a new weapon in the therapeutic strategy of multiple myeloma].

Avvisati G, Petrucci MT, Mandelli F. Avvisati G, et al. Haematologica. 1990 Jul-Aug;75 Suppl 4:68-71. Haematologica. 1990. PMID: 1705913 Review. Italian. No abstract available.

5

Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.

Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM, Marmont F, Petrucci MT, Tribalto M, Vegna ML, et al. Mandelli F, et al. Among authors: avvisati g. N Engl J Med. 1990 May 17;322(20):1430-4. doi: 10.1056/NEJM199005173222005. N Engl J Med. 1990. PMID: 2184356 Free article. Clinical Trial.

6

Alpha-2b recombinant interferon (Intron-A) as maintenance treatment in multiple myeloma.

Avvisati G, Petrucci MT, Pulsoni A, Tribalto M, Lauta VM, Gernone A, Boccadoro M, Marmont F, Pileri A, Dammacco F, et al. Avvisati G, et al. Eur J Haematol Suppl. 1990;52:9-11. doi: 10.1111/j.1600-0609.1990.tb00897.x. Eur J Haematol Suppl. 1990. PMID: 2279547 Clinical Trial. No abstract available.

7

[Therapy of multiple myeloma and its complications].

Avvisati G, Pulsoni A, Petrucci MT, Tribalto M. Avvisati G, et al. Recenti Prog Med. 1990 Oct;81(10):642-50. Recenti Prog Med. 1990. PMID: 2291008 Review. Italian.

8

High serum IL-2 levels are predictive of prolonged survival in multiple myeloma.

Cimino G, Avvisati G, Amadori S, Cava MC, Giannarelli D, Di Nucci GD, Magliocca V, Petrucci MT, Poti G, Sgadari C, et al. Cimino G, et al. Among authors: avvisati g. Br J Haematol. 1990 Jul;75(3):373-7. doi: 10.1111/j.1365-2141.1990.tb04351.x. Br J Haematol. 1990. PMID: 2386771

9

Interferon: a new strategy in the treatment of multiple myeloma.

Mandelli F, Avvisati G, Petrucci MT. Mandelli F, et al. Among authors: avvisati g. Eur J Haematol Suppl. 1989;51:129-34. doi: 10.1111/j.1600-0609.1989.tb01505.x. Eur J Haematol Suppl. 1989. PMID: 2483380 Review. No abstract available.

10

Waldenström's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients.

Petrucci MT, Avvisati G, Tribalto M, Giovangrossi P, Mandelli F. Petrucci MT, et al. Among authors: avvisati g. J Intern Med. 1989 Dec;226(6):443-7. doi: 10.1111/j.1365-2796.1989.tb01422.x. J Intern Med. 1989. PMID: 2518735

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

253 results

Search Page

Filters